Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a promising injectable cell therapy for osteoarthritis that not only lowers inflammation but also regenerates articular cartilage.
Read Full NewsA nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
1.
Two medications might work better for breast cancers that are resistant to one.
2.
Can Oncotype Predict Recurrence Risk in Older BC Patients?
3.
Surgeons are at higher risk of cancer, study suggests
4.
Kidney cancer: Understanding what a renal cell carcinoma diagnosis means
5.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
1.
Demystifying Lymphocytes: Everything You Need to Know
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge